INTRODUCTION: Acquired angioedema with C1 inhibitor deficiency (AAE-C1-INH) is rare but a potentially life-threatening disease. There are no official prevalence data, nor approved therapies for this condition. OBJECTIVE: In this study, we aimed to collect and analyze clinical data on patients with AAE-C1-INH in the Czech Republic. METHODS: We have conducted a retrospective analysis of AAE-C1-INH patients from Czech referral centers for the treatment of hereditary angioedema with C1 inhibitor deficiency. The inclusion criteria involved recurrent episodes of angioedema with the first manifestation at or after the age of 40, negative family history of angioedema, and C1 inhibitor function 50% or less. RESULTS: A total of 14 patients (7 males and 7 females) met the inclusion criteria for AAE-C1-INH. The median age of the symptom onset was 59.5 years, and the median diagnosis delay was 1 year. The most common clinical manifestation was facial edema (100%) and upper airway swelling (85.7%). All patients responded to the acute attack treatment with icatibant and plasma-derived or recombinant C1 inhibitor concentrate. Lymphoid malignancy was identified in 9 patients (64%), monoclonal gammopathy of uncertain significance in 3 (21%), and in 1 patient autoimmune disease (ulcerative colitis) was considered causative (7%). We were not able to identify any underlying disease only in 1 patient (7%). In 6 of 7 patients (86%) treated for lymphoma, either a reduction in the frequency of angioedema attacks or both angioedema symptoms' disappearance and complement parameter normalization was observed. CONCLUSIONS: The prevalence of AAE-C1-INH in the Czech Republic is about 1:760,000. This rare condition occurs in approximately 8% of the patients with angioedema with C1 inhibitor deficiency. AAE-C1-INH is strongly associated with lymphoproliferative disorders, and treating these conditions may improve the control of angioedema symptoms.

Department of Clinical Immunology and Allergology St Anne's University Hospital in Brno Faculty of Medicine Masaryk University Brno Czechia

Department of Immunology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czechia

Department of Immunology and Allergology University Hospital and Faculty of Medicine in Pilsen Pilsen Czechia

Institute of Clinical Immunology and Allergy University Hospital Hradec Kralove Faculty of Medicine Charles University Hradec Kralove Czechia

See more in PubMed

Cicardi M, Suffritti C, Perego F, Caccia S. Novelties in the diagnosis and treatment of angioedema. J Investig Allergol Clin Immunol. 2016;26((4)):212–21. PubMed

Bork K, Staubach-Renz P, Hardt J. Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate. Orphanet J Rare Dis. 2019 Mar;14((1)):65. PubMed PMC

Gobert D, Paule R, Ponard D, Levy P, Frémeaux-Bacchi V, Bouillet L, et al. A nationwide study of acquired C1-inhibitor deficiency in France: characteristics and treatment responses in 92 patients. Medicine. 2016;95:e4363. PubMed PMC

Bygum A, Vestergaard H. Acquired angioedema: occurrence, clinical features and associated disorders in a Danish nationwide patient cohort. Int Arch Allergy Immunol. 2013 Jul;162((2)):149–55. PubMed

Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014 May;69((5)):602–16. PubMed

Maurer M, Magerl M, Ansotegui I, Aygören-Pürsün E, Betschel S, Bork K, et al. The international WAO/EAACI guideline for the management of hereditary angioedema: the 2017 revision and update. Allergy. 2018 Aug;73((8)):1575–96. PubMed

Cicardi M, Zanichelli A. Acquired angioedema. Allergy Asthma Clin Immunol. 2010 Jul 28;6((1)):14. PubMed PMC

Up-to-date. Saini S. Acquired C1 inhibitor deficiency: clinical manifestations, epidemiology, pathogenesis, and diagnosis. [cited 2020 May 26]. Available from: https://www.uptodate.com/contents/acquired-c1-inhibitor-deficiency-clinical-manifestations-epidemiology-pathogenesis-and-diagnosis?search=acquired%20c1%20inhibitor%20deficiency&source=search_result&selectedTitle=1∼36&usage_type=default&display_rank=1.

Sbattella M, Zanichelli A, Ghia P, Gattei V, Suffritti C, Teatini T, et al. Splenic marginal zone lymphomas in acquired C1-inhibitor deficiency: clinical and molecular characterization. Med Oncol. 2018 Aug 2;35((9)):118. PubMed

Zanichelli A, Azin GM, Wu MA, Suffritti C, Maggioni L, Caccia S, et al. Diagnosis, course, and management of angioedema in patients with acquired C1-inhibitor deficiency. J Allergy Clin Immunol Pract. 2017 Sep-Oct;5((5)):1307–13. PubMed

Up-to-date. Saini S. Acquired C1 inhibitor deficiency: management and prognosis. [cited 2020 May 26]. Available from: https://www.uptodate.com/contents/acquired-c1-inhibitor-deficiency-management-and-prognosis?search=acquired%20c1%20inhibitor%20deficiency&source=search_result&selectedTitle=2∼36&usage_type=default&display_rank=2.

Castelli R, Zanichelli A, Cicardi M, Cugno M. Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationship. Crit Rev Oncol Hematol. 2013 Sep;87((3)):323–32. PubMed

Information from Czech statistical office. Pohyb obyvatelstva −rok 2018 [cited 2020 Jun 5]. Available from: https://www.czso.cz/csu/czso/cri/pohyb-obyvatelstva-rok-2018.

Zanichelli A, Magerl M, Longhurst H, Fabien V, Maurer M. Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. Allergy Asthma Clin Immunol. 2013 Aug;9((1)):29. PubMed PMC

Christiansen SC, Davis DK, Castaldo AJ, Zuraw BL. Pediatric hereditary angioedema: onset, diagnostic delay, and disease severity. Clin Pediatr. 2016 Sep;55((10)):935–42. PubMed